文献速递神经免疫

自体造血干细胞移植治疗活动性多发性硬化的真实世界病例系列

Autologous Hematopoietic Stem Cell Transplantation in Active Multiple Sclerosis: A Real-world Case Series.
PubMed 文献 · Neurology · 2021-07-12

该回顾性队列研究纳入英国伦敦两家中心2012至2019年连续接受自体造血干细胞移植(AHSCT)的多发性硬化患者120例,其中52%为进展型、48%为复发缓解型,基线中位EDSS为6.0。中位随访21个月,2年无复发生存率93%、4年87%,2年无新发MRI病灶率90%、4年85%,2年EDSS无进展生存率75%、4年65%;100天内移植相关死亡3例(2.5%)。作者认为真实世界疗效与严格筛选的临床试验人群相似,但风险可能更高。

要点

  • 真实世界AHSCT后2年无复发生存率93%,4年87%,与临床试验疗效相近。
  • 2年无新发MRI病灶率90%、4年85%,2年EDSS无进展生存率75%、4年65%。
  • 100天内移植相关死亡3例(2.5%),均继发于液体超负荷及心或呼吸衰竭。

核心结论

  • 真实世界队列中AHSCT的疗效结局与筛选更严格的临床试验人群相似,但风险可能更高。
  • 研究证据等级为Class IV,因为采用非对照、开放标签设计。

研究设计与样本

  • 回顾性队列研究,纳入英国伦敦2个中心2012至2019年连续接受AHSCT的多发性硬化患者。
  • 共120例,随访≥6个月或期间死亡者纳入;中位随访21个月(范围6-85个月)。
  • 52%为进展型(原发或继发进展型),48%为复发缓解型;基线中位EDSS评分6.0。

主要发现

  • AHSCT后无复发生存率2年为93%、4年为87%。
  • 2年时90%受试者无新发MRI病灶,4年时为85%。
  • EDSS无进展生存率2年为75%、4年为65%。
  • EB病毒再激活与单克隆副蛋白血症与更差的无进展生存相关。
  • 100天内移植相关死亡3例(2.5%),均发生在液体超负荷及心或呼吸衰竭之后。

关键数值与推荐

  • 可评估病例中90%在AHSCT前12个月内显示MRI活动。
  • 2年无复发生存率93%、4年87%;2年无新发MRI病灶90%、4年85%。
  • 2年EDSS无进展生存率75%、4年65%。
  • 移植相关死亡3例(2.5%),均发生于100天内。

临床怎么用

  • 对活动性多发性硬化患者,AHSCT在真实世界中可获得较高的无复发与无MRI活动生存率。
  • 需权衡移植相关死亡与心肺并发症风险,尤其关注液体超负荷及心或呼吸衰竭。
  • EB病毒再激活和单克隆副蛋白血症可能提示无进展生存较差,可作为风险分层参考。

局限性

  • 研究为非对照、开放标签设计,证据等级为Class IV。
  • 为两中心回顾性队列,样本量120例,随访时间有限。
  • 缺乏对照组,疗效比较需谨慎解读。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To examine outcomes in people with multiple sclerosis (PwMS) treated with autologous hematopoietic stem cell transplantation (AHSCT) in a real-world setting. METHODS: This was a retrospective cohort study of PwMS treated with AHSCT at 2 centers in London, UK, consecutively between 2012 and 2019 who had ≥6 months of follow-up or died at any time. Primary outcomes were survival free of multiple sclerosis (MS) relapses, MRI new lesions, and worsening of Expanded Disability Status Scale (EDSS) score. Adverse events rates were also examined. RESULTS: The cohort includes 120 PwMS; 52% had progressive MS (primary or secondary) and 48% had relapsing-remitting MS. At baseline, the median EDSS score was 6.0; 90% of the evaluable cases showed MRI activity in the 12 months preceding AHSCT. Median follow-up after AHSCT was 21 months (range 6-85 months). MS relapse-free survival was 93% at 2 years and 87% at 4 years after AHSCT. No new MRI lesions were detected in 90% of participants at 2 years and in 85% at 4 years. EDSS score progression-free survival (PFS) was 75% at 2 years and 65% at 4 years. Epstein-Barr virus reactivation and monoclonal paraproteinemia were associated with worse PFS. There were 3 transplantation-related deaths within 100 days (2.5%), all after fluid overload and cardiac or respiratory failure. CONCLUSIONS: Efficacy outcomes of AHSCT in this real-world cohort are similar to those reported in more stringently selected clinical trial populations, although the risks may be higher. CLASSIFICATION OF EVIDENCE: This study is rated Class IV because of the uncontrolled, open-label design.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Nicholas RS, Rhone EE, Mariottini A, et al. Autologous Hematopoietic Stem Cell Transplantation in Active Multiple Sclerosis: A Real-world Case Series. Neurology. 2021. PMID: 34253634. doi:10.1212/WNL.0000000000012449

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。